Clinical decision making is facilitated by healthcare professionals’ and patients’ adequate knowledge of the adverse events. This is especially important for biologicals used for treating multiple sclerosis (MS). So far, little is known about whether different information sources report adverse events consistently.

中文翻译：

---

与多发性硬化症患者使用的生物制剂有关的不良事件：来自监管机构的信息与来自科学界的信息之间的比较。

医疗保健专业人员和患者对不良事件的充分了解有助于临床决策。这对于用于治疗多发性硬化症（MS）的生物制剂尤其重要。到目前为止，对于不同的信息来源是否始终如一地报告不良事件一无所知。